Suicidal Behavior In Schizophrenia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for suicidal behavior in schizophrenia. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
1
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Suicidal Behavior In Schizophrenia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Jazz Pharmaceuticals 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating suicidal behavior in schizophrenia. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Clozaril
CLOZAPINE
 Jazz Pharmaceuticals 1 55 — 2028-05-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8057811 Clozaril formulation 55 2028-05-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8057811 Clozaril formulation 55 2028-05-01

Related